Metraipolis › archive › dc_b2f0e60b80fb
A comparative study on the efficacy and safety of biosimilar (Rimmyrah) and reference ranibizumab in patients with diabetic macular edema — Europe PMC PMID:41743118
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/41743118
- DOI
- 10.3389/fphar.2026.1773081
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-05T23:31:23.902Z
- SHA-256 of the archived text
f7ea8fdbaf44bcba0eaa70e549e85d01c9706dbc3a5fdb47c4ea67fbacfafd23- Stable URL of this page
https://metraipolis.com/documento/dc_b2f0e60b80fb
How to cite
A comparative study on the efficacy and safety of biosimilar (Rimmyrah) and reference ranibizumab in patients with diabetic macular edema — Europe PMC PMID:41743118 — Europe PMC (en), https://europepmc.org/article/MED/41743118 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_b2f0e60b80fb (Metraipolis archive dc_b2f0e60b80fb, sha256 f7ea8fdbaf44bcba0eaa70e549e85d01c9706dbc3a5fdb47c4ea67fbacfafd23)
BibTeX
@misc{dcb2f0e60b80fb,
title = {A comparative study on the efficacy and safety of biosimilar (Rimmyrah) and reference ranibizumab in patients with diabetic macular edema — Europe PMC PMID:41743118},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/41743118},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_b2f0e60b80fb; sha256 f7ea8fdbaf44bcba0eaa70e549e85d01c9706dbc3a5fdb47c4ea67fbacfafd23},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41743118. Agents can read the archived copy with the MCP tool read_document.